Stockscreener 앱 받기
8.595
3.07%
-0.245
전일 마감가:
$8.84
열려 있는:
$8.7
하루 거래량:
1.71M
Relative Volume:
0.53
시가총액:
$878.38M
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-1.5684
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
+1.04%
1개월 성능:
+29.24%
6개월 성능:
-44.47%
1년 성능:
-63.69%
1일 변동 폭
$8.45
$8.8064
1주일 범위
$7.9034
$9.2689
52주 변동 폭
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.60 | 878.38M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.01 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.78 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.28 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.91 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Genome Engineering Market Generated Opportunities, Future - openPR.com
(NTLA) Long Term Investment Analysis - news.stocktradersdaily.com
Intellia Therapeutics Inc (NTLA) Has Recovered 31.71% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Intellia Therapeutics Inc [NTLA] Records 200-Day SMA of $15.05 - knoxdaily.com
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates - The Manila Times
Leading CRISPR Pioneer Intellia Therapeutics to Reveal Q1 2025 Financial Results and Pipeline Updates - Stock Titan
The growth track for Intellia Therapeutics Inc (NTLA) has changed recently - Sete News
Company’s Banking Stock: Dissecting a -16.35% Quarterly Revenue Decline Amid Growth - investchronicle.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Intellia Therapeutics Inc’s results are impressive - uspostnews.com
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet - Yahoo Finance
Upward Trajectory: Intellia Therapeutics Inc (NTLA) Posts a Gaine, Closing at 8.48 - DWinneX
Intellia Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA - ACCESS Newswire
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Cathie Wood’s ARK offloads Meta, boosts Intellia stock - Investing.com Australia
Cathie Wood’s ARK offloads Meta, boosts Intellia stock By Investing.com - Investing.com Canada
Is Intellia Therapeutics Inc (NASDAQ:NTLA) A Better Buy Than Others After A -62.53% Fall In This Year? - Marketing Sentinel
Insider Sale Alert: Intellia Therapeutics Inc [NTLA] – Is it Time to sell? - knoxdaily.com
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation - Morningstar
Wolfe Research Upgrades Intellia Therapeutics (LSE:0JBU) - Nasdaq
Wolfe Research Upgrades Intellia Therapeutics (NTLA) - Nasdaq
Intellia Therapeutics shares up after Wolfe upgrade - MSN
Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research - marketscreener.com
Intellia Therapeutics (NTLA) Surges After Upgrade from Wolfe Research - GuruFocus
NTLA’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Intellia Therapeutics (NTLA) Advances Nex-z in Phase III Trial f - GuruFocus
Intellia Therapeutics (NTLA) Receives Upgrade to Outperform from Wolfe Research | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Eyes Growth with Gene Editing Advances - GuruFocus
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
New Horizons in Biomedical CRISPR Gene Editing Market Exploring - openPR.com
Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21 - marketscreener.com
How the (NTLA) price action is used to our Advantage - news.stocktradersdaily.com
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The ... - Bluefield Daily Telegraph
Intellia Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
Final Deadline Today for the Intellia Therapeutics, Inc. Securit - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Final Deadline Today for the Intellia Therapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsNTLA - The Malaysian Reserve
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA)April 14, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Business Wire
FINAL REMINDER NTLA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Intellia Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - markets.businessinsider.com
NTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc. - TipRanks
Intellia Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA - PR Newswire
NTLA Deadline: NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
FINAL NTLA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Intellia Therapeutics, Inc. Investors to Join the Class Action Lawsuit - markets.businessinsider.com
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Intellia Therapeutics Inc 주식 (NTLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
| BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '25 |
Sale |
12.18 |
9,557 |
116,404 |
87,666 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '25 |
Sale |
12.18 |
6,502 |
79,194 |
59,878 |
| LEONARD JOHN M | President and CEO |
Jan 03 '25 |
Sale |
12.18 |
26,807 |
326,509 |
941,115 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '25 |
Sale |
12.18 |
8,966 |
109,206 |
77,388 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 03 '25 |
Sale |
12.18 |
7,422 |
90,400 |
64,048 |
0.27%
0.30%
자본화:
|
볼륨(24시간):